Breaking News, Collaborations & Alliances

Circio, Entos Enter Research Collaboration Focused on Circular RNA Delivery

Circio’s circVec DNA vectors will be combined with Entos’ Fusogenix PLV delivery technology.

Author Image

By: Charlie Sternberg

Associate Editor

Circio Holding ASA, a biotechnology company developing circular RNA technology for next-generation nucleic acid medicine, and Entos Pharmaceuticals U.K. Ltd., a clinical-stage genetic medicines company, have initiated a research collaboration that will involve joint development and in vivo delivery testing of Circio’s optimized circular RNA expression vectors (circVec) using the Entos proprietary Fusogenix PLV nucleic acid delivery technology. Under the collaboration, Entos will develop and v...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters